Practically the best ’omics
Multiomics is changing how molecular medicine is done. Nightingale Health now offers multiple ‘omics technologies to accelerate your research, all from a single blood sample and through one simplified workflow.
Nightingale Health for Research is your Multiomics Hub
One blood sample. One partner. Multiomics.
Access multiple layers of ’omics data in one place. We now offer metabolomics and proteomics that set the benchmark. Our platform also supports deeper exploration through additional services including genomics and metabolomic risk scores.
Kickstart your research with CoreMetabolomics
Metabolomics is where our story began, and it remains at the core of what we do today.
Our CoreMetabolomics service measures lipids, inflammation, dietary intake, insulin sensitivity, and more – reproducibly and cost-effectively. Our biomarkers are associated with diverse aspects of human health, from cardiometabolic disease to kidney and liver function to dementia and mental health.
The biomarkers also reflect the exposome, including smoking and diet, and provide crucial baseline data for your study.
Now available: Metabolomics + Proteomics
CoreMetabolomics by Nightingale Health gives absolute concentrations for key metabolites that sit at the heart of biology — lipids, fatty acids, amino acids, sugars, and ketones. These values compare cleanly across cohorts and time, so trends and effect sizes are easy to read.
Add proteomics to track proteins linked to inflammation, tissue stress, or neurodegeneration, and reveal actors and signals tied to those metabolic changes. The combination lets you connect changes you can quantify in serum chemistry with the proteins that drive or reflect them.
Unlock deeper insights with additional services
Beyond metabolomics and proteomics, we offer additional insights from the same sample material. For a more complete health picture, we offer advanced risk profiling, HbA1c, and Lp(a) risk testing.
Our technology is trusted by researchers worldwide
Replication unlike anywhere else
Nightingale Health’s comprehensive biomarker profiling technology has measured samples from global biobanks and cohort studies. This has created the world’s largest virtual biobank, where scientists worldwide can collaborate and replicate their findings.
Multiomics at the scale of the world’s largest biobanks and cohorts
Our research service provides comprehensive multiomics profiling for entire cohorts. Since our 'omics technology has been used to measure across all 500,000 participants in the UK Biobank and 200,000 participants in the Estonian Biobank, you can discover hidden biology in the world's biggest health research datasets.
Nightingale Biomarker-Disease Atlas
We are proud to have partnered with these world-leading medical research studies and that our data is available to qualified researchers to amplify and replicate new research findings and increase impact. You can also explore our atlas of biobank associations in UK Biobank.
See our upcoming webinars
Our new research insights
New multiomics horizons: Nightingale Health now offers Alamar NULISA CNS and Inflammation proteomics
Nov 11, 2025
Urine Metabolite Profiling: From Studies of Diabetes Patients to General Population Cohorts
May 08, 2025
Meet us at upcoming events
Diabetes Canada/CSEM Professional Conference
26.11. – 29.11.2025
Toronto, Canada
UK Biobank Scientific Conference
8.12.2025
London, UK
The Festival of Genomics & Biodata
28.1. – 29.1.2026
London, UK
Customer testimonials
Publications using Nightingale Health technology
Metabolomic profiles predict individual multidisease outcomes
Buergel et al., Nat Med., 2022
The ground-breaking study conducted by researchers from universities in Germany, the Netherlands, and the UK on over 100,000 people demonstrates how one blood test can identify early risk signs for many common diseases. The unique snapshot of a person’s health state captured by Nightingale Health’s proprietary metabolomic blood test was able to improve current health screening tools for several costly diseases, such as heart failure, dementia, and diabetes.
Atlas of plasma NMR biomarkers for health and disease in 118,461 individuals from the UK Biobank
Julkunen et al, Nat Com., 2023
The associations between Nightingale Biomarkers and common chronic diseases like cardiovascular disease or type 2 diabetes have been studied for years. However, in recent studies with data from the UK Biobank, like this oneboth by our internal science team as well as independent study groups, the key findings have been that our biomarkers can predict hundreds of disease endpoints. These findings open countless opportunities to scientists, as they receive not only the wide biomarker panel analyzed from a single blood sample, but also open access to the UK Biobank data which enables them to replicate the study findings in the selection of hundreds of thousands of individuals.
Genome-wide characterization of circulating metabolic biomarkers
Karjalainen et al., Nature, 2024
A genome-wide association study involving 136,000 participants from 33 cohorts (including cohorts like INTERVAL, PROSPER and TUK), identified genetic determinants of 233 circulating metabolic biomarkers analyzed by Nightingale Health. The study found over 8,000 genetic associations across 400 independent loci and identified probable causal genes for two-thirds of these loci through manual curation. The authors emphasize the influence of sample and participant characteristics on the associations, though the inclusion of 33 different cohorts allowed for many robust findings. Comprehensive metabolic profiling was used to explore the impact of known and novel genetic loci on lipoprotein metabolism. Through the public release of their summary statistics, the authors offer new detailed insights into the genetic regulation of metabolism to the whole research community.